tldrdaily.news logo

J&J's CAR-T Therapy Shows Promising Results in Lymphoma Trials

1 min read
Source: Fierce Biotech
J&J's CAR-T Therapy Shows Promising Results in Lymphoma Trials
Photo: Fierce Biotech
TL;DR Summary

Johnson & Johnson's early-stage clinical trial of a dual-targeting CAR-T therapy for lymphoma shows promising results, with a 100% response rate in patients with prior treatment, and manageable safety profile, marking a significant step forward in blood cancer treatment.

Topics:business#cancer-treatment#car-t-therapy#clinical-trial#healthcare#johnson-and-johnson#lymphoma
Share this article
  1. J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients  Fierce Biotech
  2. Dr Ku on the Safety Profile of JNJ-90014496 in Relapsed/Refractory LBCL  OncLive
  3. EHA25: J&J's next CAR-T contender shows near-universal responses in LBCL  FirstWord
  4. Johnson & Johnson's (JNJ) CAR T-cell Therapy Shows Promising Results in Trials  GuruFocus
  5. JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL  CancerNetwork

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

2 min

vs 3 min read

Condensed

92%

481 → 39 words

Want the full story? Read the original article

Read on Fierce Biotech